Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-04-21Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
-
CLINICAL_TRIALS study record update · 2022-04-07A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma
-
CLINICAL_TRIALS study record update · 2022-03-31Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications
-
CLINICAL_TRIALS study record update · 2022-03-31A Global Enhanced Pharmacovigilance Pregnancy Surveillance Study of Pregnant Women Exposed to Yervoy With 5 -Year Pediatric Follow-up
-
CLINICAL_TRIALS study record update · 2022-03-31A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-03-29A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
-
CLINICAL_TRIALS study record update · 2022-03-29A Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
-
CLINICAL_TRIALS study record update · 2022-03-22Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
-
CLINICAL_TRIALS study record update · 2022-03-21A National, Prospective, Non- Interventional Study (NIS) in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma and Subsequent Treatments in Case of Relapse
-
CLINICAL_TRIALS study record update · 2022-03-17Individual Patient Compassionate Use of GX-I7
-
CLINICAL_TRIALS study record update · 2022-03-16Integrated Basic Science Within the Instructional Design of Pattern Recognition Training in Visual Diagnostics: Effect on Learning Curve Steepness, Plateau and Retrieval
-
CLINICAL_TRIALS study record update · 2022-02-28Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-24Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
-
CLINICAL_TRIALS study record update · 2022-02-11Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
-
CLINICAL_TRIALS study record update · 2022-02-10Understanding the Treatment Patterns, Healthcare Resource Utilization, Costs of Care, and Clinical Outcomes Among Patients Treated for Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-08A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
-
CLINICAL_TRIALS study record update · 2022-02-08Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
-
CLINICAL_TRIALS study record update · 2022-02-08Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-08A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
-
CLINICAL_TRIALS study record update · 2022-02-08A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)
-
CLINICAL_TRIALS study record update · 2022-02-04Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-01Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study
-
CLINICAL_TRIALS study record update · 2022-01-26Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
-
CLINICAL_TRIALS study record update · 2022-01-04SunSmart Intervention in Schools
-
CLINICAL_TRIALS study record update · 2022-01-03Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma